5 Obesity Readouts to Watch in the Second Half of 2024

Hundreds of companies are currently running clinical trials in the increasingly lucrative obesity space. BioSpace looks at five candidates with data expected before the end of the year.

With a quarter of the world’s population expected to have obesity by 2035 and the market for obesity therapeutics predicted to hit $131 billion within the next five years, it’s no wonder the disease is one of biopharma’s hottest targets. While the space is currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, several other candidates are making their way through the pipeline, their makers aiming to snag a piece of the lucrative pie.